학술논문

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
Document Type
Article
Author
Sibbing, DirkAradi, DánielJacobshagen, ClaudiusGross, LisaTrenk, DietmarGeisler, TobiasOrban, MartinHadamitzky, MartinMerkely, BélaKiss, Róbert GáborKomócsi, AndrásDézsi, Csaba AHoldt, LescaFelix, Stephan BParma, RadoslawKlopotowski, MariuszSchwinger, Robert H GRieber, JohannesHuber, KurtNeumann, Franz-JosefKoltowski, LukaszMehilli, JulindaHuczek, ZenonMassberg, SteffenParma, RadoslawParma, ZofiaLesiak, MaciejKomosa, AnnaHuczek, ZenonKoltowski, LukaszKowara, MichalRymuza, BartoszKlopotowski, MariuszMalek, LukaszAradi, DanielVeress, GáborDézsi, András DömeMerkely, BélaLux, ÁrpádKiss, Róbert GáborPapp, JuditKovács, AndreaDézsi, Csaba AndrásAmer, SayourRuzsa, ZoltánRóna, SzilárdKomócsi, AndrásIli, RenátaUngi, ImreNagy, FerencZweiker, RobertTóth-Gayor, GáborHuber, KurtHaller, Paulvon Scheidt, WolfgangBlüthgen, AndreasNeumann, Franz-JosefTrenk, DietmarLeggewie, StefanKreider-Stempfle, Hans UlrichRemp, ThomasKara, KafferMügge, AndreasWutzler, AlexanderFichtlscherer, StephanZeiher, Andreas M.Seeger, FlorianHinterseer, MartinKönig, AndreasLederle, SusanneJacobshagen, ClaudiusCzepluch, FraukeMaier, LarsSchillinger, WolfgangSossalla, SamuelHummel, AstridFelix, StephanKarakas, MahirSydow, KarstenRudolph, TanjaHalbach, MarcelGori, TommasoMünzel, ThomasMay, AndreasGerstenberg, Carsten-ManuelPilecky, DavidRieber, JohannesDeichstetter, MarkusSibbing, DirkMehilli, JulindaGross, LisaKääb, StefanLöw, AnjaOrban, MartinOrban, MatthiasSattler, StefanDeuschl, SabineTeupser, DanielHoldt, LescaMudra, HaraldRäder, ThomasSchütz, TorstenVahldiek, FelixDivchev, DimitarInce, HüseyinNienaber, Christoph ARadunski, HenningBoekstegers, PeterHorstkotte, JanMueller, RalfGeisler, TobiasMüller, KarinSchwinger, RobertRasp, Oliver
Source
The Lancet; October 2017, Vol. 390 Issue: 10104 p1747-1757, 11p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous coronary intervention (PCI). However, the greatest anti-ischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding events arise during chronic treatment. Hence, a stage-adapted treatment with potent platelet inhibition in the acute phase and de-escalation to clopidogrel in the maintenance phase could be an alternative approach. We aimed to investigate the safety and efficacy of early de-escalation of antiplatelet treatment from prasugrel to clopidogrel guided by platelet function testing (PFT).